8-K: BioSig Amends Debenture Deal, Adds Dilution Safeguards

BioSig Technologies, Inc. amended its secured convertible debenture purchase agreement with Yorkville, restructuring the financing to include a conversion floor price and mutual agreement for future tranches.

Summary

• BioSig Technologies, Inc. entered into an Amendment to its Secured Convertible Debenture Purchase Agreement with YA II PN, LTD. (Yorkville) on August 13, 2025.
• The amendment revises the structure of the transaction, providing for a first secured convertible debenture of $25,000,000 and a second secured convertible debenture of $25,000,000.
• Additional secured convertible debentures up to an aggregate principal amount of $50,000,000 can be issued only upon mutual agreement of both parties, with either party having the sole discretion to withhold agreement.
• The purchase price for the debentures is set at 96.0% of the principal amount.
• A new floor price for conversions has been established at 20% of the Nasdaq Official Closing Price immediately prior to July 7, 2025.
• The Company is required to hold a special or annual meeting of stockholders within 90 calendar days of August 13, 2025, to obtain approval for the issuance of the debentures and conversion shares, as well as shares issuable under a separate SEPA agreement.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the financing is dilutive, the amendment introduces protective measures for the company, such as a conversion floor price and more control over future tranches, which mitigate some of the negative aspects of convertible debt.

Positives

• The amendment introduces a conversion floor price set at 20% of the Nasdaq Official Closing Price prior to July 7, 2025, which provides a safeguard against excessive dilution at very low stock prices.
• The issuance of the additional $50,000,000 in debentures is now subject to mutual agreement, granting BioSig Technologies, Inc. more control and discretion over future capital raises from this source.

Negatives

• The financing structure involves convertible debentures, which will lead to future dilution of existing shareholders upon conversion.
• The purchase price of 96.0% of the principal amount means the company receives less than the face value of the debt, effectively incurring a discount on the capital raised.

Risks

• Significant dilution risk for existing shareholders due to the conversion of the secured convertible debentures into common shares.
• Uncertainty regarding the availability of the final $50,000,000 tranche, as its issuance is contingent on mutual agreement, which either party can withhold.
• Failure to obtain required stockholder approvals for the debenture issuance and conversion shares within 90 days could lead to adverse consequences for the financing agreement.

Future Outlook

The company anticipates securing up to $100,000,000 in financing through secured convertible debentures, with the final $50,000,000 tranche contingent on mutual agreement. Future actions include holding a stockholder meeting within 90 days to approve the debenture issuance and related share issuances.

Management Comments

• Henry McPhie, Chief Executive Officer, signed the report on behalf of BioSig Technologies, Inc.

Industry Context

This amendment reflects a common strategy for smaller biotechnology or medical device companies like BioSig Technologies, Inc. to secure capital through dilutive financing instruments. The inclusion of a conversion floor price and mutual agreement for later tranches indicates a move to protect the company's equity value and maintain control over future funding, which is a prudent step in a volatile market for growth-stage companies.

Comparison to Industry Standards

• The 96.0% purchase price (4% discount) for convertible debentures is within the typical range for such financing deals, which often include discounts or original issue discounts (OIDs) to compensate investors for the risk and the convertible feature.
• The inclusion of a conversion floor price is a positive deviation from some standard convertible debt structures, offering more protection against extreme dilution compared to agreements without such a floor, which can be critical for companies with volatile stock prices.
• The mutual agreement clause for the final $50 million tranche provides BioSig with more flexibility than a fully committed facility, allowing them to assess capital needs and market conditions before drawing additional funds, similar to staged financing common in early-to-mid stage companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the conversion of debentures into common stock. However, the new conversion floor price offers some protection against extreme dilution at very low stock prices.
• Creditors/Investors (YA II PN, LTD.): The amendment clarifies terms and conditions, including the purchase price and conversion floor, providing a structured investment framework. The mutual agreement clause for the final tranche gives them discretion over further investment.
• Company Operations: Secures significant capital (up to $100M) to fund operations, research, and development, which is crucial for a growth-stage technology company.

Next Steps

• The Company must hold a special or annual meeting of stockholders within 90 calendar days of August 13, 2025, to obtain approval for the issuance of the Secured Convertible Debentures and the Maximum Conversion Shares.
• The Company must also obtain stockholder approval for the issuance of Common Shares issuable pursuant to the SEPA.

Key Dates

Recommendation

The company is securing substantial financing, which is crucial for its operations and growth. The amendment introduces terms that are more favorable to the company by mitigating dilution risk with a conversion floor and providing more control over future capital draws. However, the financing is still dilutive, and the company's operational performance and long-term prospects are not detailed in this filing. Therefore, a 'hold' recommendation is appropriate for investors to observe how this capital is deployed and its impact on the company's fundamentals before making further investment decisions.

Keywords

Convertible Debenture, Secured Financing, Capital Raise, Dilution, Stockholder Approval, Nasdaq, BioSig Technologies, BSGM, Yorkville